Devices, digital health, and the technology changing how care is delivered.
IKS Health acquired TruBridge for $557 million, folding the rural-hospital-focused EHR and revenue cycle company into its AI-powered care platform. It’s IKS’ third acquisition this year. The post IKS Health Beefs Up Its Tech Stack with $557M Acquisition of TruBridge appeared first on MedCity News .
With the acquisition of Robocath completed, Stereotaxis intends to accelerate development of next-generation robotic technologies for endovascular procedures.
The Advanced Research Projects Agency for Health has awarded a new tranche of funds for companies and institutions developing personalized genetic medicines, with the recipient list dominated by high-profile players in the buzzy field.
After Idorsia’s former chief, Srishti Gupta, M.D., left the company upon “mutual agreement” in March, the Swiss drugmaker has now tapped a new leader, Roland Wandeler, Ph.D. Wandeler will officially take over from interim CEO and board chairman Jean-Paul Clozel, M.D., come October 1.
The draft agreement outlines the Food and Drug Administration’s goals for medical device reviews from 2028 to 2032.
For someone already managing chronic disease, menopause can disrupt stability and complicate treatment plans in ways that aren’t always immediately visible but show up over time in outcomes and utilization. The post Menopause Is an Overlooked Driver of Cost in High-Risk Populations appeared first on MedCity News .
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.
“We have all this data that’s available, but it’s actually not actionable because we don’t have a way to get it into clinical workflow,” said American Medical Association CEO Dr. John Whyte.
The organizations that move now — with the right foundation and the right partners — will enter the next planning cycle with a specialty pharmacy that functions as a true strategic asset. The post Specialty Pharmacy Is No Longer Optional Infrastructure appeared first on MedCity News .
Non-surgical implantable BCI is increasingly capable of matching surgical performance while transforming the risk-benefit equation, and it is now the most credible path along all three dimensions simultaneously. The post Brain Interfaces Don’t Need Surgery to Be Transformative – and the Distinction Is Now a Strategic One appeared first on MedCity News .
Illumina has filled two key C-suite posts, naming Mike Sullivan as chief commercial officer and Julie Coletti as chief legal officer as the DNA sequencing giant works to keep its turnaround on track after years of regulatory, geopolitical and investor turbulence.
“We were not expecting to see clinical responses so early,” Vaneet Sandhu, M.D., rheumatologist and vice president of clinical development at Fate Therapeutics, told Fierce.
More than 4,000 Brigham and Women’s Hospital nurses and 450 home health workers launched Massachusetts’ largest-ever healthcare strike this week over stalled contract talks on wages and benefits. The strike quickly prompted Governor Maura Healey to step in and convene both sides at the State House, but it remains unclear whether a deal is near. The post MGB Nurses, Home Health Staff Launch Strike Over Wages, Benefits appeared first on MedCity News .
Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA’s move away from reliance on animal testing towards organoid, organ-on-a-chip, and other in silico technologies. A Connecticut startup believes whole-organ testing should be an essential part of this mix. The post Organ-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On It appeared first on MedCity News .
Selling the software business to Frazier Healthcare Partners will allow the respiratory device maker to shift more resources to faster-growing parts of its portfolio.
Penumbra, which is set to become part of Boston Scientific this year, is running the trial to inform the treatment of a type of medium-vessel blockage.
Focusing on fringe cases of abuse misses a more immediate and arguably more pervasive problem: many provider organizations are not getting the access to IDR they’re entitled to because the process is too difficult to navigate effectively at scale. The post Why the Future of IDR Depends on Smarter Technology appeared first on MedCity News .
For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents, longer stealth periods and even some misdirection can be required to ensure drug developers retain an edge.
Clinical integration is not achieved through governance structures alone. It depends on whether the organization has developed the operational capabilities required to execute consistently across markets that historically functioned independently. The post What Health Systems Miss When Building National Service Lines appeared first on MedCity News .
The market for robotic surgery got more competitive this year, with Medtronic, Stryker, CMR Surgical and Distalmotion introducing new platforms. Check up on their progress and more in MedTech Dive’s roundup of robotics coverage.
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma company in April.
Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ruled that the company did not violate its agreement with Beam and can continue developing its lead asset for alpha-1 antitrypsin deficiency.
Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy drug candidate is active in adults, leading analysts to predict the molecule “could re-imagine the ... therapeutic landscape” if the biotech replicates the data in children.
Precision immunology company Scipher Medicine will absorb Chemomab Therapeutics after having identified the Israeli biotech’s liver disease drug as the ideal fit for its own expertise.